Can epigenetics shine a light on the biological pathways underlying major mental disorders?

Luis Alameda1,2, Giulia Trotta3, Harriet Quigley1, Victoria Rodriguez1, Romayne Gadelrab4, Daniella Dwir5, Emma Dempster6, Chloe C. Y. Wong3,* and Marta Di Forti3,7,*

1Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK; 2Department of Psychiatry, Centre for Affective Disorders, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK; 3Centre for Affective Disorders, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK; 4Department of Psychiatry, Center for Psychiatric Neuroscience, Lausanne University Hospital (CHUV), Lausanne, Switzerland; 5University of Exeter Medical School, University of Exeter, Barrack Road, Exeter, UK and 6South London and Maudsley NHS Foundation Trust, London, UK

Received: 19 June 2021
Revised: 30 November 2021
Accepted: 29 December 2021
First published online: 23 February 2022

Keywords:
Epigenetics; childhood trauma; DNA-methylation; mental health disorders

Abstract
A significant proportion of the global burden of disease can be attributed to mental illness. Despite important advances in identifying risk factors for mental health conditions, the biological processing underlying causal pathways to disease onset remain poorly understood. This represents a limitation to implement effective prevention and the development of novel pharmacological treatments. Epigenetic mechanisms have emerged as mediators of environmental and genetic risk factors which might play a role in disease onset, including childhood adversity (CA) and cannabis use (CU). Particularly, human research exploring DNA methylation has provided new and promising insights into the role of biological pathways implicated in the aetio-pathogenesis of psychiatric conditions, including: monoaminergic (Serotonin and Dopamine), GABAergic, glutamatergic, neurogenesis, inflammatory and immune response and oxidative stress. While these epigenetic changes have been often studied as disease-specific, similarly to the investigation of environmental risk factors, they are often transdiagnostic. Therefore, we aim to review the existing literature on DNA methylation from human studies of psychiatric diseases (i) to identify epigenetic modifications mapping onto biological pathways either transdiagnostically or specifically related to psychiatric diseases such as Eating Disorders, Post-traumatic Stress Disorder, Bipolar and Psychotic Disorder, Depression, Autism Spectrum Disorder and Anxiety Disorder, and (ii) to investigate a convergence between some of these epigenetic modifications and the exposure to known risk factors for psychiatric disorders such as CA and CU, as well as to other epigenetic confounders in psychiatry research.

Introduction of main epigenetic processes in psychiatry research
Both genetic and environmental factors are implicated in the aetiology of psychiatric disorders, however, the key causal mechanisms for guiding effective prevention and treatment remain poorly understood (Van Os, Rutten, & Poulton, 2008). Genetic association studies (Ripke et al., 2014) as well as epidemiological studies addressing the impact of the environment (van Os, Kenis, & Rutten, 2010) on disease burden, have not yet explained the non-complete genetic correlation between monozygotic twins in conditions such as schizophrenia (SCZ) (41–65%), Bipolar Disorder (BD) (∼60%) (Craddock, O'Donovan, & Owen, 2005) or Major Depression (MDD) (∼40%) (Ripke et al., 2013).

In the past decade, growing evidence has shown a link between epigenetic processes, and a range of mental health disorders (Binder, 2017). Epigenetic modifications refer to functional changes in DNA structural packaging or associated proteins without structural alteration of the DNA sequence itself (Jaenisch & Bird, 2003). This biological mechanism has important implications on how genes are expressed and how the chromatin is packaged, thus modifying subsequent protein translation within regionally specific parts of the central nervous system (Binder, 2017). The most studied epigenetic process in humans is DNA methylation (DNAm) (Table 1 for definitions of key terms). Indeed, recent parallel evidence suggests that differential DNAm profiles are associated with exposure to childhood adversity (CA) as well as cannabis use (CU) (Kandaswamy et al., 2020; Markunas et al., 2020; Nöthling, Malan-Müller, Abrahams, Hemmings, & Seedat, 2020). This suggests that epigenetic factors may account for some of the non-explained variance in genetics studies and possibly mediate
### Table 1. A glossary of key epigenetic terms and biological function of genes involved in pathways discussed in this review

| Gene names and key terms | Biological function and definition |
|-------------------------|----------------------------------|
| **Epigenetic terms**    |                                   |
| DNA-methylation         | DNA-meth is the covalent addition of a methyl group to the 5th carbon of a Cytosine (C) base, resulting in a 5-methylcytosine (5-mC) base. Epigenetic is the major process by which the environment can alter gene expression. |
| Candidate gene approach | Explores methylation on certain genes of interests based on a priory hypothesis. It often examines whether DNAm changes in different CG sites within specific genes are related to a particular phenotype. |
| Epigenome-Wide Association Studies | Examines the association of DNAm changes (otherwise called methylome-wide association studies (MWAS)) across the entire genome for a particular phenotype, using a hypothesis-free paradigm. EWAS have been performed with increasingly powerful techniques and have moved from pioneer CpG-island microarrays studies that interrogated around 12,000 sites across the DNA (Mill et al., 2008) to more advanced techniques such as Infinium MethylationsEPIC BeadChip, that covers more than 850,000 CpG methylation sites (Yong et al., 2016). |
| Histone acetylation studies | Histone acetylation is a dynamic epigenetic modification that functions in the regulation of DNA-templated reactions, such as transcription. This lysine modification is reversibly controlled by histone (lysine) acetyltransferases and deacetylases. |
| Methylome-wide association studies (MWAS) | Test a genome-wide set of methylation sites for association with an outcome of interest. |
| **Serotonergic pathway** |                                   |
| SLC6A4                  | Regulated serotonergic signalling via transporting 5-HT from synaptic spaces into presynaptic neurons. SLCA2 is involved in the recapture of the Norepinephrine |
| 5-HTR (1A, 2A, 2B 3A, 5A) | These genes encode for the receptors for the neurotransmitter serotonin |
| A (MAOA)                | One of two neighbouring gene family members that encode mitochondrial enzymes which catalyse the oxidative deamination of amines, such as dopamine, norepinephrine, and serotonin |
| **Dopaminergic pathway** |                                   |
| DRD (2', 3, 4)          | Encode different subtypes of the dopamine receptor |
| COMT(D1)                | Encodes for Catechol-O-methyltransferase enzyme, which catalyses the transfer of a methyl group from S-adenosylmethionine to catecholamines, including the neurotransmitters dopamine, epinephrine, and norepinephrine important in the degradation of Dopamine (DA) |
| DAT1*                   | The dopamine transporter is implicated in a number of dopamine-related disorders, including attention deficit hyperactivity disorder, bipolar disorder, clinical depression, alcoholism, and substance use disorder |
| FAM63B                  | Involved in four networks regulated by miRNA, three of which are linked to neuronal differentiation and dopaminergic gene expression |
| SLC6A3                  | Provides instructions for making a protein called the dopamine transporter or DAT |
| **Glutamatergic/GABAergic pathway** |                                   |
| GAD1                    | Encodes one of several forms of glutamic acid decarboxylase, an enzyme which is responsible for catalysing the production of gamma-aminobutyric acid from L-glutamic acid |
| PIALB                   | Encodes for Parvalbumin protein, essential for neural synchronisation in some neurons in the CNS |
| GRIN1 (2,2B 3B, D1)     | The protein encoded by this gene is a critical subunit of N-methyl-D-aspartate receptors, members of the glutamate receptor channel superfamily. It plays an important role in the plasticity of synapses |
| GRIA 2, 3               | Encodes for the Glutamate Ionotropic Receptor AMPA Type Subunit 2 and 3 Glutamate receptors, which are the predominant excitatory neurotransmitter receptors in the mammalian brain |
| MARLIN-1                | (synonym of JAKMIP1) codes for a protein that may play a role in the microtubule-dependent transport of the GABA-B receptor |
| KCNJ6                   | Encodes a member of the G protein-coupled inwardly-rectifying potassium channel family of inward rectifier potassium channels. This type of potassium channel allows a greater flow of potassium into the cell than out of it and thus regulates circuit activities in neural cells. Expressed in GABAergic synapses |
| HELT                    | Protein Coding gene involved in DNA-binding transcription factor activity and protein dimerisation activity. It is a transcriptional repressor gene which is known to function as a selector gene that determines GABAergic over glutamatergic fate in the mesencephalon |
| GRIK2                   | Codes for the Glutamate Ionotropic Receptor Kainate Type Subunit 2. Glutamate receptors are the predominant excitatory neurotransmitter receptors in the mammalian brain |
| SLC6A12                 | Transports betaine and GABA. May have a role in the regulation of GABAergic transmission in the brain through the reuptake of GABA into presynaptic terminals, as well as in osmotic regulation. |
| GABBR1, 2               | Encodes a receptor for GABA that functions as a heterodimer with GABAB receptor 1 and 2. Defects in this gene may underlie brain disorders such as schizophrenia and epilepsy. |

(Continued)
| Gene names and key terms | Biological function and definition |
|-------------------------|----------------------------------|
| **GRIN3B**              | The protein encoded by this gene is a subunit of an N-methyl-D-aspartate (NMDA) receptor. The encoded protein is found primarily in motor neurons, where it forms a heterotetramer with GRIN1 to create an excitatory glycine receptor. Variations in this gene have been proposed to be linked to schizophrenia. |
| **Neurogenesis**        | This gene encodes a large secreted extracellular matrix protein (Reelin) thought to control cell-cell interactions critical for cell positioning and neuronal migration during brain development. Expressed in GABAergic interneurons. |
| **BDNF**                | Encodes the brain-derived neurotrophic factor (BDNF), a protein involved in promoting the survival, growth and differentiation of new neurons and synapses. |
| **POUSF1, POU6F2, POU3F1** | Encodes a transcription factor protein that binds to the octamer motif (5-ATTTGCAT-3) and controls myelination (thought to be involved in embryogenesis and neurogenesis). |
| **NPDC1**               | Encodes a protein that Suppresses oncogenic transformation in neural and non-neural cells and down-regulates neural cell proliferation. Might be involved in transcriptional regulation. |
| **PI3K**                | Phosphatidylinositol 3-kinases, are a family of enzymes involved in cellular functions such as cell growth, proliferation, differentiation, motility, survival and intracellular trafficking. |
| **CUXI**                | Encodes a member of the homeodomain family of DNA binding proteins that regulates gene expression, morphogenesis, and differentiation and it also plays a role in cell cycle progression. |
| **CLMN**                | Encodes calmin (calponin-like transmembrane domain protein). |
| **SENPT7**              | Encodes sentrin-specific protease 7. |
| **Immune system and inflammation** |
| **ZC3H12D**             | It is a Protein (Zinc Finger CCCH-Type Containing 12D) Coding gene, which in association with ZC3H12A enhances the degradation of interleukin IL-6 mRNA level in activated macrophages, among other functions. |
| **TCF3**                | This gene encodes a member of the E protein (class I) family of helix-loop-helix transcription factors. E proteins play a critical role in lymphopoiesis, and the encoded protein is required for B and T lymphocyte development, among other functions. |
| **IKZF4**               | Members of the Ikaros family of transcription factors, which includes Eos, are expressed in lymphocytes and are implicated in the control of lymphoid development. |
| **YOD1**                | Protein ubiquitination controls many intracellular processes, including cell cycle progression, transcriptional activation, and signal transduction, involved in IL-1 signalling to NF-kB. |
| **IL17RA**              | Code for Interleukin 17A (IL17A), which is a proinflammatory cytokine secreted by activated T-lymphocytes. |
| **TLR1 (3)**            | Encodes Toll-Like Receptor 1, family which plays a fundamental role in pathogen recognition and activation of innate immunity. |
| **TNFRSF13C**           | TNF Receptor Superfamily Member 13C, a membrane protein of the TNF receptor superfamily which recognises BAFF, an essential factor for B cell maturation and survival. |
| **HERC5**               | This gene is a member of the HERC family of ubiquitin ligases and encodes a protein with a HECT domain and five RING repeats. Pro-inflammatory cytokines upregulate expression of this gene in endothelial cells. |
| **FCGR2B**              | One of the genes thought to influence susceptibility to several autoimmune diseases in humans inhibiting the functions of activating FcγRs, such as phagocytosis and pro-inflammatory cytokine release. |
| **PIK3R3**              | Plays an important role in the regulation of cellular lipid metabolism. |
| **INPP5D**              | Encodes Src homology 2 (SH2) domain-containing inositol polyphosphate 5-phosphatase 1 (SHIP1) that functions as a negative regulator of cell proliferation and survival. |
| **FCGR2C, 2B**          | Encodes one of three members of a family of low-affinity immunoglobulin gamma Fc receptors found on the surface of many immune response cells and involved in phagocytosis. |
| **IGHA1**               | Encodes a constant (C) segment of Immunoglobulin A heavy chain that plays a critical role in immune function in the mucous membranes. |
| **FCAR**                | Codes for the transmembrane receptor FcαRI, also known as CD89 (Cluster of Differentiation 89), that plays a role in both pro- and anti-inflammatory responses. |
| **CD224**               | This is a human gamma-glutamyltransferase catalyses the transfer of the glutamyl moiety of glutathione to a variety of amino acids and dipeptide acceptors. |
| **LAX1**                | A membrane-associated adaptor protein mainly expressed in B cells, T cells, and other lymphoid-specific cell types. |
| **TXK**                 | A member of Tec family nonreceptor tyrosine kinase, is expressed on Th1/Th0 cells, and Txk regulates specifically IFN-gamma gene expression. |

(Continued)
the interactions between genotype and known environmental risk factors in influencing the onset of complex diseases (Relton & Smith, 2010).

Initially, epigenetic research in psychiatry used a candidate gene approach, and progressively, research moved to Epigenome Wide Association studies (EWAS) (Table 1). While both designs have their advantages and limitations, the breadth of coverage of EWAS offers a more informative insight on biological pathways. This is based on the rational that chromatin conformation and transcriptional regulation are influenced by a set of methylated or unmethylated cytosines across a region, rather than specific CpG sites in isolation (Mill et al., 2008).

Different biological pathways have been implicated in the etio-pathogenesis across multiple mental disorders. Some of these are pathways related to neurotransmission such as serotonin (Provenzi, Giorda, Beri, & Montirosso, 2016), dopamine or GABA/glutamatergic processes (McCutcheon, Krystal, & Howes, 2020); while others pathways involve inflammation (Cullen et al., 2019), oxidative stress (Steele et al., 2016), synaptic plasticity and neurogenesis (Claudino, Gonçalves, Schuch, Martins, Table 1. (Continued.)

| Gene names and key terms | Biological function and definition |
|--------------------------|----------------------------------|
| Encodes perforin, a pore-forming cytolytic protein found in the granules of cytotoxic T lymphocytes (CTLs) and natural killer cells (NK cells) |
| Encodes a transmembrane protein which is a member of the immunoglobulin superfamily found on thymocytes and mature T cells that plays an essential role in T-cell interactions and also in T-cell/B-cell interaction during early lymphoid development |
| Encodes N-methylpurine DNA glycosylase, a specific type of DNA glycosylase involved in the recognition of a variety of base lesions, including alkylated and deaminated purines, and initiating their repair via the base excision repair pathway |
| A member of the XPO subfamily of peroxidase enzyme most abundantly expressed in neutrophil granulocytes |
| The protein encoded by this gene is an enzyme found in the outer mitochondrial membrane that reduces N-hydroxylated substrates |
| Cell migration-inducing and hyaluronal-binding protein, known as KIAA1199, has been shown to bind hyaluronic acid and catalyse its depolymerisation its depolymerisation independently of CD44 and hyaluronidases |
| Encodes a gamma-glutamyltransferase, that plays a key role in glutathione homeostasis by providing substrates for its synthesis |
| (Glutathione S-Transferase Mu 5), important for glutathione homeostasis |
| Encodes the human glucocorticoid receptor protein, which is the receptor to which cortisol and other glucocorticoids bind |
| A microRNA that targets NR3C1 |
| Encodes the FK506 binding protein, a member of the immunophilin protein family which may play a role in immunoregulation and basic cellular processes involving protein folding and trafficking |
| Encodes for a component of the spindle and kinetochore-associated protein complex, which is a protein complex involved in regulating chromosomal segregation. SKA2 is important in facilitating GR nuclear transactivation. |
| Encodes the cannabinoid receptor gene |
| This gene encodes an enzyme that transfers methyl groups to cytosine nucleotides of genomic DNA |
| Encodes oxytocin, which is a neuropeptide hormone produced by the hypothalamus and released into systemic circulation by the posterior pituitary |
| The protein encoded by this gene participates in the aryl hydrocarbon receptor (AhR) signalling cascade, which mediates dioxin toxicity, and is involved in the regulation of cell growth and differentiation |
| Encodes a member of the protease-activated receptor subfamily, part of the G-protein coupled receptor 1 family of proteins. This receptor plays a role in blood coagulation, inflammation and response to pain |
| Encodes a nuclear zinc finger protein that functions as a transcriptional repressor. This protein plays a role in diverse developmental contexts, including haematopoiesis and oncogenesis |
| Is a plasma membrane-associated class I myosin that is abundant in T and B lymphocytes and mast cells. This myosin is required during immune response for detection of rare antigen-presenting cells by regulating T-cell migration |

*genes related to cannabis use.
Evidence of epigenetic processes in major transdiagnostic pathways

In this section we will review the evidence, predominantly from case–control studies pointing at an association between DNAm changes in the Serotoninergic, Dopaminergic pathways, Excitatory inhibitory balance (including the Glutamatergic and GABAergic dysfunction), Synaptic plasticity and Neurogenesis; the Immune system, Inflammation and Oxidative stress and the major mental conditions (focusing on Eating Disorders (ED): anorexia nervosa (AN) and bulimia nervosa (BN), Autism Spectrum Disorder (ASD), BD and Psychotic Disorder, Depression, Post Traumatic Stress Disorder (PTSD) and Anxiety Disorders). Summary of findings is illustrated in Fig. 1; findings on HPA-axis and its association to environmental risk (Pariente, 2017). Although these processes are often explored within discrete categorical clinical conditions, they often overlap transdagnostically. For instance, alterations in serotonin pathways are linked to both depression and psychosis phenotypes (Selvaraj, Arnone, Cappai, & Howes, 2014).

In this review, we set to appraise firstly, the evidence of DNAm modifications both from candidate genes and EWAS studies, associated either specifically or transdiagnostically with psychiatric conditions, and secondly, if these DNAm modifications map onto biological pathways. Thirdly, we will explore if the existing findings from studies on DNAm changes associated with CA and CU, two of the environmental exposures most consistently associated with psychiatric disorders (Lindert et al., 2014; Mandelli, Petrelli, & Serretti, 2015; Marconi, Di Forti, Lewis, Murray, & Vassos, 2016; Sidel, Quigley, La Cascia, & Murray, 2020a; Varese et al., 2012), point at the same biological pathways therefore contributing to the understanding of how these environmental exposures increase transdiagnostic and specific psychiatric liability. Details on methodological considerations can be found in Online Supplementary Material (SM).

The serotoninergic pathway

There are preclinical and human studies pointing at an implication of the serotonin (5HT) system dysfunction in a broad range of psychiatric diseases (Kaye, Fudge, & Paulus, 2009). The strongest evidence is at the level of the serotonin transported genes (mainly SLC6A4) with candidate genes studies suggesting an increased in methylation in depression (Kang et al., 2013; Philibert et al., 2008; Zhao, Goldberg, Bremner, & Vaccarino, 2013), BD (Sugawara et al., 2011) and reporting a positive association with symptoms severity (Olsson et al., 2010), comorbid depression in those with panic disorder (Schiele et al., 2019), and improvement from baseline to follow-up (Perez-Cornago, Mansego, Zulet, & Martinez, 2014). It has been suggested that an increased DNAm of SLC6A4 could repress gene expression, leading to decreased serotonin uptake and lower activity, which ultimately would lead to the manifestation of depressive symptoms (Chen, Meng, Pei, Zheng, & Leng, 2017).

A pattern of hypermethylation has also been found in samples of SCZ (Abdolmaleky et al., 2014), although with mixed evidence (Alezu-Paz et al., 2015). Candidate gene studies in SCZ and BD across various tissues (Abdolmaleky et al., 2011; Carrard, Salzmann, Malafosse, & Karege, 2011; Cheah, Lawford, Young, Morris, & Voisey, 2017) show elevated DNAm of the 5-HTR1A and 5-HTR2A genes respectively. Further, EWAS studies have identified differential DNAm in HTR2A (Numata, Ye, Herman, & Lipska, 2014), HTR5A and HTR1E (Nishioka et al., 2015; Pidsley et al., 2014) genes in those with psychosis.

Evidence on ED so far has not found an association with SLC6A4 DNAm and AN (Boehm et al., 2019; Pjetri et al., 2013; Steiger et al., 2019).

In ASD, preliminary evidence indicated higher HTR2A promoter DNAm in leucocytes of those carrying the high-risk genotype in the HTR2A (Hranilovic, Blazevic, Stefulj, & Zill, 2016).

Another well-explored gene of interest in the serotoninergic pathway is MAO-A (Shih & Thompson, 1999) which is involved in monoamine degradation and it has established linked with depression (Meyer et al., 2006). While studies in depression have found inconsistent DNAm changes (Domschke et al., 2015; Melas & Forsell, 2015; Melas et al., 2013); in candidate gene studies in anxiety disorders, the evidence points at a pattern of hypomethylation (Ziegler et al., 2016) as shown in acrophobia (Schiele et al., 2018) and obsessive compulsive disorder (OCD) (Domschke et al., 2012). Moreover, increased MAO-A DNAm has been suggested as a potential useful marker of better response to psychotherapy in anxiety disorders (Schiele et al., 2020; Ziegler et al., 2016).

Overall, we find a transdiagnostic link between DNAm changes in genes involved in the serotoninergic pathway, with limited evidence in ED (findings on PTSD discussed in Section ‘The epigenetic signature of childhood adversity and cannabis use’ and described in Table 2).

The dopaminergic pathway

It is widely accepted that dopaminergic dysregulation stands as one of the most supported hypotheses for the pathogenesis of SCZ and psychosis as a whole (Jauhar et al., 2018; McCutcheon et al., 2020). Studies examining DNAm in the blood of patients with SCZ as compared with controls have showed both higher and lower DNAm levels in different DA receptor’s genes; with decreased DNAm in DRD3 (Dai et al., 2014) and DRD4 (Cheng et al., 2014); and in other dopamine receptors (Kordi-Tamandani, Sahranavard, & Torkamanzehi, 2013b; Yoshino et al., 2016).

Hypomethylation of the COMT membrane-bound isoform, has been identified in samples of people with SCZ across tissues (Abdolmaleky et al., 2006; Nohesara et al., 2011; Nour El Huda et al., 2018; Walton et al., 2014), while the soluble isoform (S-COMT) has been reported to be hypermethylated (Melas et al., 2012; Murphy, O’Reilly, & Singh, 2005). EWAS studies comparing SCZ patients with controls have found
hypomethylation of SLC6A3, a dopamine transporter (Nishioka et al., 2013), COMTD1 and FAM63B, a gene linked to dopaminergic gene expression (Aberg et al., 2014).

In ED, findings of DNAm changes affecting dopaminergic genes DAT and DRD2 are mixed (Friel et al., 2010; Pjetri et al., 2013). It has been suggested that DNAm variation in the dopamine pathway in ED may be related to comorbidity Borderline Personality Disorder (Borderline PD) (Groleau et al., 2014) and exposure to CA (Section ‘The epigenetic signature of childhood adversity and cannabis use’ and Online Supplementary Table S1 (SM)).

None of the EWAS studies conducted in ASD has found evidence supporting an association with DNAm changes involved in the Dopaminergic pathway.

Overall, recent findings support a link between DNAm changes in genes involved in the dopaminergic pathway related to neurodevelopmental disorders such as SCZ, with limited evidence suggesting a link with other conditions.

Glutamatergic/GABAergic Pathway and excitatory/inhibitory balance

Alterations in glutamatergic and GABAergic pathways, which can lead to either excitatory/inhibitory imbalance, have been reported to play a role in the etiopathogenesis of psychotic disorders (McCutcheon et al., 2020) and ASD (Marotta et al., 2020). Furthermore, N-Methyl-D-aspartate or N-Methyl-D-aspartate (NMDAR) hypofunction as well as a decrease in the parvalbumin-expressing fast-spiking interneurons (PVI), both processes being essential for the excitatory/inhibitory balance, have been widely shown to be involved in psychotic disorders (Thuné, Recasens, & Uhlhaas, 2016).
In SCZ and psychosis, there is evidence from candidate genes studies across tissues supporting DNAm differences between cases and controls in genes such as the Parvalbumin (PVALB) gene (Fachim, Srisawat, Dalton, & Reynolds, 2018), GMR2 and GMR5 of the glutamatergic receptors (Kordi-Tamandani, Dahmardeh, & Torkamanzehi, 2013a); various CpG sites in the β2 subunit of the GABAa receptor gene (GABRB2) (Pun et al., 2011; Zong et al., 2017), and in GRIN2B, involved in the function of NMDAR (Fachim et al., 2019). A dysregulation of multiple DNAm positions in the regulatory network of GAD1, was identified in patients with SCZ and BD compared to controls (Ruzicka, Subburaju, & Benes, 2015).

In terms of EWAS, Mill and colleagues (Mill et al., 2008) performed the first EWAS in post-mortem brains of SCZ and BD subjects compared to controls, and found DNAm changes associated with SCZ and BD at loci involved in glutamatergic (GRIA 2, GRIND3B) and GABAergic (MARLIN-1, KCNJ6, RELN, HELT) neurotransmission, supporting previous candidate genes results. Findings related to GRIA family genes have been replicated in latter EWAS studies (Aberg et al., 2012; Numata et al., 2014), and other EWAS studies have confirmed DNAm changes in genes involving GABAergic neurotransmission (SLC6A12 and GABBR1) (Hannon et al., 2021).

In ASD, an EWAS study on histone acetylation in participants with the disorder compared to controls found an enrichment of hyperacetylated sites in genes involved in GABA receptor activity (Ramaswami et al., 2020), although this has not been previously found on DNAm (Wong et al., 2018).

Lastly, a Depression EWAS (Nagy et al., 2015) of post-mortem brains of suicide victims and controls found 115 differentially methylated regions (DMRs), which included regions related to GRIK2.

Overall, there is evidence linking DNAm changes on genes involved in the glutamatergic pathway mainly with psychosis, with some evidence suggesting a link with ASD and MDD.

**Synaptic plasticity and neurogenesis**

Synaptic plasticity anomalies are associated with psychiatric conditions and may account for various symptoms, such as cognitive deficits (Claudino et al., 2020; Di Carlo, Punzi, & Ursini, 2019; Lin & Huang, 2020).

RELN is a good studies gene that has been linked to SCZ (Costa et al., 2002). An aberrant DNAm status in RELN has been found in SCZ and BD patient as compared with controls (Fikri et al., 2017; Tamura, Kunugi, Ohashi, & Hohjoh, 2007).
Table 2. Summary of the direction of the associations between DNAm, mental health disorders and clinical or biological outcomes presented in this review

| Gene (hyper ↑ or ↓ hypo DNAm) and citation | Candidate gene or EWAS | Tissue | Condition/sample | Clinical/biological outcome |
|--------------------------------------------|-------------------------|--------|-----------------|-----------------------------|
| **Serotonergic pathway**                   |                         |        |                 |                             |
| SLC6A4                                     |                         |        |                 |                             |
| ↑Abdolmaleky et al. (2014)                  | Candidate gene          | PMB/   | SCZ             |                             |
| Kang et al. (2013)                         | Candidate gene          | Blood  | Depression      | CA → ↑SLC6A4 → clinical severity |
| Olsson et al. (2010)                       | Candidate gene          | Buccal | Depression      | ↑SLC6A4 → ↑ Depressive symptoms |
| ↑Philibert et al. (2008)                   | Candidate gene          | Blood  | Depression      | ↑SLC6A4 → ↑ history MDD     |
| ↑Zhao et al. (2013)                        | Candidate gene          | Blood  | Twin male veterans | ↑SLC6A4 → ↑ Depressive symptoms |
| Perez-Cornago et al. (2014)                | Candidate gene          | Blood  | General population | ↑SLC6A4 → decrease depressive symptoms from baseline to Follow-up |
| Boehm et al. (2019)                        | Candidate gene          | Blood  | Anorexia nervosa | ↑SLC6A4 → resting-state functional connectivity → anorexia symptoms |
| Koenen et al. (2011)                       | Candidate gene          | Blood  | PTSD            | CA + ↓SLC6A4 → PTSD          |
| Peng et al. (2018)                         | Candidate gene          | Blood  | General population | CA → ↑SLC6A4 → depressive symptoms |
| Schiele et al. (2019)                      | Candidate gene          | Blood  | Panic disorder  | ↑SLC6A4 → Comorbid depression |
| 5-HT1A                                     |                         |        |                 |                             |
| ↑Carrard et al. (2011)                     | Candidate gene          | Blood  | SCZ/BD          |                             |
| 5-HT2A                                     |                         |        |                 |                             |
| ↑Cheah et al. (2017)                       | Candidate gene          | PMB    | SCZ             |                             |
| ↑Abdolmaleky et al. (2011)                 | Candidate gene          | PMB    | SCZ/BD          |                             |
| ↑Hranilovic et al. (2016)                  | Candidate gene          | Blood  | ASD             |                             |
| 5-HT3A-R                                   |                         |        |                 |                             |
| ↑Perroud et al. (2016)                     | Candidate gene          | Blood  | BD/Borderline PD | CA → ↑5-HT3A-R → clinical severity |
| A MAOA                                     |                         |        |                 |                             |
| ↓ Ziegler et al. (2016)                    | Candidate gene          | Blood  | Panic disorder  | ↑ → Better response to CBT in agoraphobic symptoms |
| ↓Schiele et al. (2018)                     | Candidate gene          | Blood  | Agoraphobia     |                             |
| ↓Domschke et al. (2012)                    | Candidate gene          | Blood  | Panic disorder  | CA → ↓A (MAOA)              |
| Peng et al. (2018)                         | Candidate gene          | Blood  | General population | CA → ↓A (MAOA) → depressive symptoms |
| **Dopaminergic pathway**                   |                         |        |                 |                             |
| DRD2                                       |                         |        |                 |                             |
| ↑Kordi-Tamandani et al. (2013b)            | Candidate gene          | Blood  | SCZ             |                             |
| ↓Yoshino et al. (2016)                     | Candidate gene          | Blood  | SCZ             |                             |
| ↑Frieling et al. (2010)                    | Candidate gene          | Blood  | Anorexia and bulimia nervosa |                             |
| DRD3                                       |                         |        |                 |                             |
| ↑Dai et al. (2014)                         | Candidate gene          | Blood  | SCZ             |                             |
| DRD4                                       |                         |        |                 |                             |
| ↑Cheng et al. (2014)                       | Candidate gene          | Blood  | SCZ             |                             |
| ↑Kordi-Tamandani et al. (2013b)            | Candidate gene          | Blood  | SCZ             |                             |
| DRD5                                       |                         |        |                 |                             |
| ↑Kordi-Tamandani et al. (2013b)            | Candidate gene          | Blood  | SCZ             |                             |
| MB-COMT                                    |                         |        |                 |                             |
| ↓Abdolmaleky et al. (2006)                 | Candidate gene          | PMB    | SCZ/BD          |                             |

(Continued)
| Gene (hyper ↑ or ↓ hypo DNAm) and citation | Candidate gene or EWAS | Tissue | Condition/sample | Clinical/biological outcome |
|-------------------------------------------|-------------------------|--------|------------------|-----------------------------|
| ↓Nohesara et al. (2011) Candidate gene   | Saliva                  | SCZ/BD |                  |                             |
| Walton et al. (2014) Candidate gene       | Blood                   | SCZ    |                  | ↑ MB-COMT → better neural activity in left DLPFC |
| ↓Nour El Huda et al. (2018) Candidate gene| Blood                   | SCZ    |                  | ↑ MB-COMT → ↓ excited and depressed symptoms |
| S-COMT                                    |                         |        |                  |                             |
| ↑Murphy et al. (2005) Candidate gene      | Blood                   | SCZ    |                  |                             |
| ↑Melas et al. (2012) Candidate gene       | Blood                   | SCZ    |                  |                             |
| COMT1                                     |                         |        |                  |                             |
| ↓Nishioka et al. (2013) EWAS              | Blood                   | SCZ    |                  |                             |
| SLC6A3                                    |                         |        |                  |                             |
| ↓Nishioka et al. (2013) EWAS              | Blood                   | SCZ    |                  |                             |
| DAT1*                                     |                         |        |                  |                             |
| ↑Frielings et al. (2010) Candidate gene   | Blood                   | Anorexia and bulimia nervosa |                             |
| FAM63B                                    |                         |        |                  |                             |
| ↓Aberg et al. (2012) EWAS                 | Blood                   | SCZ    |                  |                             |
| Glutamatergic/GABAergic pathway (Excitatory/inhibitory balance) | | | | |
| PIK3L                                     |                         |        |                  |                             |
| ↑Fachim et al. (2018) Candidate gene      | PMB                     | SCZ    |                  |                             |
| GMR2, GMR5                                |                         |        |                  |                             |
| ↓Kordi-Tamandani et al. (2013a) Candidate gene | Blood                   | SCZ    |                  |                             |
| GRIA 1                                    |                         |        |                  |                             |
| ↑Kordi-Tamandani et al. (2013a) Candidate gene | Blood                   | SCZ    |                  |                             |
| GRIA 2                                    |                         |        |                  |                             |
| ↓Mill et al. (2008) EWAS                  | PMB                     | SCZ/BD |                  |                             |
| ↓Aberg et al. (2012) EWAS                 | Blood                   | SCZ    |                  |                             |
| GRIA 4                                    |                         |        |                  |                             |
| ↑Numata et al. (2014) EWAS                | PMB                     | SCZ    |                  |                             |
| GABBR1                                    |                         |        |                  |                             |
| ↑Hannon et al. (2021) EWAS                | Blood                   | SCZ    |                  |                             |
| GABBR2                                    |                         |        |                  |                             |
| ↑Pun et al. (2011) Candidate gene         | Blood                   | SCZ    |                  |                             |
| ↑Zong et al. (2017) Candidate gene         | Blood                   | SCZ    |                  |                             |
| GRIN 2B                                   |                         |        |                  | CA → ↑ GRIN2B |
| Engdahl et al. (2021) Candidate gene       | Saliva                  | General population |                  |                             |
| GRIND1                                    |                         |        |                  |                             |
| Weder et al. (2014) EWAS                  | Saliva                  | Trauma/non-trauma children |                  |                             |
| GAD1                                      |                         |        |                  |                             |
| Ruzicka et al. (2015) Candidate gene       | PMB                     | SCZ/BD |                  |                             |
| ↓Domshchke et al. (2013) Candidate gene    | Blood                   | SCZ    | Panic disorder    | Life events → ↓GAD1 DNAm |

(Continued)
| Gene (hyper↑ or hypo↓ DNAm) and citation | Candidate gene or EWAS | Tissue | Condition/sample | Clinical/biological outcome |
|----------------------------------------|------------------------|--------|-----------------|---------------------------|
| GRIN3B                                 | EWAS                   | PMB    | SCZ/BD          |                           |
| Mill et al. (2008)                     | EWAS                   | PMB    | SCZ/BD          |                           |
| MARLIN-1                               | EWAS                   | PMB    | SCZ/BD          |                           |
| Mill et al. (2008)                     | EWAS                   | PMB    | SCZ/BD          |                           |
| KCNJ6                                  | EWAS                   | PMB    | SCZ/BD          |                           |
| Mill et al. (2008)                     | EWAS                   | PMB    | SCZ/BD          |                           |
| HELT                                   | EWAS                   | PMB    | SCZ/BD          |                           |
| Mill et al. (2008)                     | EWAS                   | PMB    | SCZ/BD          |                           |
| GRIK2                                  | EWAS                   | PMB    | SCZ/BD          |                           |
| Nagy et al. (2015)                     | EWAS                   | PMB    | Depression      |                           |
| SLC6A12                                | EWAS                   | Blood  | Psychosis and SCZ |                           |

**Synaptic plasticity and neurogenesis**

| RELN                                   | Candidate gene         | PMB    | SCZ/BD          | ↓DNAm → poor cognition    |
|----------------------------------------|------------------------|--------|-----------------|---------------------------|
| Tamura et al. (2007)                   | Candidate gene         | Blood  | SCZ             |                           |
| Alfimova et al. (2018)                 | Candidate gene         | Blood  | SCZ             |                           |
| Fikri et al. (2017)                    | Candidate gene         | Blood  | SCZ             |                           |
| PI3K                                   | EWAS                   | PMB    | ASD             |                           |
| BDNF                                   | Candidate gene         | Blood  | SCZ             |                           |
| Ursini et al. (2016)                   | Candidate gene         | Blood  | SCZ             |                           |
| Duffy et al. (2019)                    | Candidate gene         | Blood  | BD              |                           |
| Dell et al. (2014)                     | Candidate gene         | Blood  | Unipolar, BD and MDD |                           |
| Kim et al. (2017)                      | Candidate gene         | Blood  | PTSD            |                           |
| Kang et al. (2015)*                    | Candidate gene         | Blood  | Depression      | ↑BDNF→↑depressive symptoms |
| Peng et al. (2018)                     | Candidate gene         | Blood  | Depression      | CA -> ↑BDNF→ depressive symptoms |
| Thomas et al. (2018)                   | Candidate gene         | Blood  | Borderline PD   |                           |
| D’Addario et al. (2019)                | Candidate gene         | Blood  | OCD             |                           |
| Thaler et al. (2014)                   | Candidate gene         | Blood  | Bulimia nervosa | CA + Borderline PD →↑BDNF meth |
| Moser et al. (2015)                    | EWAS                   | Saliva | PTSD            | CA → ↑BDNF meth / ↑BDNF meth-> maternal anxiety |
| Weder et al. (2014)                    | EWAS                   | Saliva | Trauma/non-trauma children | Differently methylated between CA + and CA- |
| POU6F2                                 | EWAS                   | Blood  | BD              | ↑CA→↓POU6F2               |
| Comes et al. (2020)                    | EWAS                   | Blood  | BD              |                           |
| POU5F1                                 | EWAS                   | Blood  | Borderline PD   | ↑CA→↓POU5F1               |
| POU3F1                                 | EWAS                   | Blood  | Depression      | ↑CA→↓POU3F1               |
| CUX1*                                  | EWAS                   | Blood  | General population | Differently methylated in CU (exploratory analyses) |

(Continued)
## Table 2. (Continued.)

| Gene (hyper ↑ or hypo DNAm) and citation | Candidate gene or EWAS | Tissue | Condition/sample | Clinical/biological outcome |
|------------------------------------------|------------------------|--------|------------------|----------------------------|
| **CLMN**, **SENPI**                      | EWAS                   | Blood  | Adolescents      | Differently methylated in CU users |
| **Immune system and inflammation**       |                        |        |                  |                            |
| ZC3H12D                                  | EWAS                   | Blood  | SCZ              |                            |
| ↓Montano et al. (2016)                    | EWAS                   | Blood  | SCZ              |                            |
| TCF3                                     | EWAS                   | Blood  | SCZ              |                            |
| IKZF4                                    | EWAS                   | Blood  | SCZ              |                            |
| ↓Montano et al. (2016)                    | EWAS                   | Blood  | SCZ              |                            |
| YOD1                                     | EWAS                   | PMB    | Depression       |                            |
| IL1TRA                                   | Prados et al. (2015)   | EWAS   | Blood            | Borderline PD/depression   |
| CA → ↑ IL1TRA                            |                        |        |                  |                            |
| TLR1 3                                   | Uddin et al. (2010)    | EWAS   | Blood            | PTSD                        |
| CA → ↓ TLR1/3                            |                        |        |                  |                            |
| TNFRF13C                                 | Arranz et al. (2021)   | EWAS   | Blood            | Borderline PD               |
| ↑Differently methylated in CA exposed     |                        |        |                  |                            |
| FCGR2B, PIK3R3, INPP5D, INPP5D, IGMA1, FCAR | EWAS                   | Blood  | SCZ              |                            |
| Aberg et al. (2014)                      | CD224, LAX1, TXK, PRF1, CD7, MPG, MPOG | EWAS | Blood | SCZ | |
| Liu et al. (2014)                         |                       |        |                  |                            |
| MARC2*                                   | Osborne et al. (2020)  | EWAS   | Blood            | General population          |
| CEMIP*                                   | EWAS                   | Blood  | General population | Differently methylated in CU and tobacco users |
| Markunas et al. (2020)                    |                       |        |                  |                            |
| **Oxidative stress**                     |                        |        |                  |                            |
| ↑GSTM5                                   | Kebir et al. (2017)    | EWAS   | Blood            | At the risk of psychosis   |
| ↑GSTM5 in converters v. non-converters   |                        |        |                  |                            |
| GGT6                                     | Arranz et al. (2021)   | EWAS   | Blood            | Borderline PD               |
| **Hypothalamus pituitary-adrenal axis pathway** |                        |        |                  |                            |
| NR3CI                                    | Bustamante et al. (2016) | Candidate gene | Blood | Depression | CA → ↓ NR3CI DNAm |
| Farrell et al. (2018)                     | Candidate gene         | Blood  | Depression       | CA → ↑ NR3CI DNAm          |
| Martin-Blanco et al. (2014)               | Candidate gene         | Blood  | Borderline PD    | CA → ↑ NR3CI DNAm→ clinical severity |
| Perroud et al. (2011)                     | Candidate gene         | Blood  | Borderline PD /MDD | CA→ ↑ NR3CI DNAm |
| Radtke et al. (2015)                      | Candidate gene         | Blood  | General population | CA + ↑ NR3CI DNAm → Borderline PD symptoms |
| Labonte et al. (2014)                     | Candidate gene         | Blood  | PTSD             | PTSD + → ↓ NR3CI DNAm |
| Schechter et al. (2015)                   | Candidate gene         | Saliva | PTSD             | PTSD + → ↓ NR3CI DNAm |

(Continued)
Interestingly, peripheral blood hypomethylation in the RELN promoter was associated with poor cognitive functioning (Allimova, Kondratiev, Golov, & Golimbet, 2018).

In ASD, an EWAS study in post-mortem brain found dysregulation in the pathway of phosphatidylinositol 3-kinase (PI3K) activity (Wong et al., 2019), an enzyme that is involved in cellular growth, proliferation and differentiation, and which has been previously been associated with SCZ (Law et al., 2012).

Brain-derived Neurotrophic factor (BDNF) is essential for neurogenesis and extensively studied as a biomarker in psychiatry (Lin & Huang, 2020). There is extensive evidence of a difference in DNAm in BDNF, as well as EWAS studies showing enrichment for the neurogenesis pathway in SCZ (Di Carlo et al., 2019; Ursini et al., 2016), BD (Dell et al., 2014; Duffy et al., 2019), PTSD (Kim et al., 2017; Uddin et al., 2010), Depression (Hing, Sathyaputri, & Potash, 2018; Kang et al., 2015), Borderline PD (Arranz et al., 2021; Thomas et al., 2018), Anxiety Disorders (D’Addario et al., 2019), ED (Thaler et al., 2014), ASD (Ramaswami et al., 2020) thus making a well-replicated epigenetic transdiagnostic finding in psychiatry.

As a whole, transdiagnostic evidence suggests an involvement of DNAm changes in neurogenesis an neural plasticity.

**Immune system and inflammation**

Abundant evidence supports the role of neuroinflammation and altered immune processes in the aetiopathogeneses of various mental conditions (Mazza, Lucchi, Rossetti, & Clerici, 2020; Pariente, 2017).

An EWAS by Montano et al. (Montano et al. 2016) found differences in DNAm in genes involved in T-cell development in the blood of SCZ patients (ZC3H12D, TCF3, and IKZF4); other EWAS have also reported an enrichment in the immune system pathway by differently methylated genes (FR2B, PIK3R3, INPP5D, FCGR2C, IGH1A, FCAR, CD224, LAX1, TXK, PRF1, CD7, MPG, and MPOG) (Aberg et al., 2014; Hannon et al., 2016; Liu et al., 2014).

In depression, a discordant monozygotic twin study based on peripheral blood, found 39 DMRs associated to a lifetime history of MDD, which were significantly enriched in biological pathways associated to cytokine secretion (Zhu et al., 2020). Another EWAS on post-mortem brain of people with late-MDD (Hüls et al., 2020), found altered DNAm in the YOD1 locus, which is dysregulated in depression (Howren, Lamkin, & Suls, 2009) and its implicated in the regulation of inflammatory processes (Schimmack et al., 2017).

Two EWAS studies in PTSD found differences in DNAm across genes part of biological pathways involved with inflammation and immune response (Kuan et al., 2017; Uddin et al., 2010).

In ASD, various EWAS studies have pointed at dysregulation of pathways related to immune response (Ramaswami et al., 2020; Wong et al., 2019), and in a genome-wide microRNA (miRNA) expression profiling study (Wu, Parikshak, Belgard, & Geschwind, 2016).

Furthermore, an EWAS study from patients suffering from Panic Disorder found enrichment in genes involved in the regulation of lymphocytes (Shimada-Sugimoto et al., 2017).

We can conclude that there is transdiagnostic, rather than specific, a link between DNAm changes in the immune system and inflammation and neural plasticity, although evidence is more robust in SCZ.

**Oxidative stress**

There is converging evidence pointing at a role of redox dysregulation as a possible mechanism involved in the aetiopathogenesis of both ASD (Bierklund et al., 2020) and psychosis (Perkins, Jeffries, & Do, 2020). Oxidative stress has been shown to play a role in epigenetic modifications, enhancing inflammatory gene transcription (Rahman, Marwick, & Kirkham, 2004). Oxidation of 5mC to the 5-hydroxymethylcytosine (5hmC) is considered a key step in the reversibility of DNA methylation, which can have important therapeutic implications. Moreover, glutathione,
the major antioxidant in the brain, is involved in the methionine cycle, and depletion of glutathione can be detrimental for the DNAm process (García-Giménez, Roma-Mateo, Perez-Machado, Peiro-Chova, & Pallardó, 2017).

Although evidence examining this pathway in the context of epigenetics is scarce, some EWAS have shown interesting results: one study examined prospectively the association of EWAS methylation changes with the transition to psychosis (Kebrir et al., 2017), and found an enrichment of pathways related to oxidative stress regulation in those transitioning. Furthermore, an EWAS study in Borderline PD found differences in methylation in GCT6, which is important in glutathione metabolism (Arranz et al., 2021).

The epigenetic signature of childhood adversity and cannabis use

The characteristics of the studies described in this section can be found in Online Supplementary Table S1 (SM), and in Table 2.

Hypothalamus pituitary-adrenal axis pathway

While multiple studies have explored the link between epigenetic modification involved in the HPA-axis, and psychiatric disorders, recent evidence is beginning to indicate that some of these epigenetic modifications might follow exposure to CA. The latter is a robustly replicated risk factor for many psychiatric disorders (Online Supplementary Table S1 (SM) summarises the main findings on studies examining the link between DNAm and genes involved in the HPA-axis, and key findings are summarised in Fig. 2). As a whole, as illustrated in Fig. 2, at the level of NR3C1 there is consistent evidence on a positive correlation between CA and DNAm in Borderline PD and MDD and some clinical outcomes (Farrell et al., 2018; Martin-Blanco et al., 2014; Perroud et al., 2011; Radtke et al., 2015), and a negative correlation with anxiety and PTSD (Labonte, Azoulay, Yerko, Turecki, & Brunet, 2014; Schechter et al., 2015; Wang et al., 2017; Yehuda et al., 2015). Lower DNAm in FKBP5 is associated with CA in psychosis and PTSD (Klengel et al., 2013; Misjak et al., 2020); while in depression, 3 studies found no such link (Bustamante et al., 2018; Farrell et al., 2018; Klinger-König et al., 2019), as opposed to another study (Tozzi et al., 2018). As for NR3C1, findings on FKBP5 DNAm are different across disorder, suggesting a divergent transdiagnostic mechanism involving in HPA related genes (see Fig. 2). The SKA2 interacts with adversity scores in predicting lifetime suicide attempt (Kaminsky et al., 2015), and mediated the association between reduced cortical thickness and PTSD (Sadeh et al., 2016a) and suicide phenotypes (Sadeh et al., 2016b).

Serotonergic, dopaminergic and glutamatergic/GABAAergic pathways

Childhood adversity

With regards to the serotonergic pathway, while hypomethylation in SLC6A4 is associated with resilience to PTSD (Koenen et al., 2011), hypermethylation of SLC6A4 has been linked to exposure to CA and associated with the worst clinical presentation in MDD (Kang et al., 2013). Moreover, hypermethylation in the 5-HT3A-R gene appeared to mediate the link between exposure to adversity and higher severity of disease parameters in a mixed sample of BD and Borderline PD (Perroud et al., 2016).

Moreover, hypomethylation of MAOA, a gene important for the degradation of serotonin and DA (Xu, Jiang, Gu, Wang, & Yuan, 2020), appears to partially mediate the known association between CA and depressive symptoms, alongside with other stress-related genes such as BDNF and NR3C1 and SLC64 (Peng et al., 2018). Moreover, MAOA DNAm was negatively correlated to life events in a sample of Panic Disorder (Domschke et al., 2012).

In relation to DA, one study in patients with bulimia spectrum disorders found no differences in DRD2 DNAm when comparing those with exposure and non-exposure to trauma (Groleau et al., 2014).

At the level of the Glutamatergic pathway, one study found that exposure to CA was associated with decreased DNAm in GAD in a sample of Panic Disorder (Domschke et al., 2013). Lastly, a candidate gene study (Engdahl, Alavian-Ghavanini, Forsell, Lavebratt, & Rüegg, 2021) and an EWAS (Weder et al., 2014) linked CA to increased methylation levels in GRIN2B/GRIND1 genes, suggesting evidence that this change may lead to the onset of depressive symptoms.

As a whole, DNAm changes in some of the genes that have been previously linked to major psychiatric conditions (Section 'Evidence of epigenetic processes in major transdiagnostic pathways', Table 2), such as SLC6A4, 5HT3A-R, A (MAOA), BDNF, GAD, and the GRIND family, (related to the serotonergic, and glutamatergic pathways respectively) are also associated to CA. This suggests that some of the DNAm changes attributed to these disorders may be partially related to the consequence of CA exposure, as illustrated in Fig. 1.

Cannabis use

CU and in particular heavy use (Marconi et al., 2016) has been consistently associated with increased risk for PD, but to a lesser degree for other psychiatric conditions (Sideli, Trotta, Spinazzola, La Cascia, & Di Forti, 2020b). In recent years, candidate genes studies from peripheral blood have reported changes in DNAm associated with heavy CU in genes involved in dopamine transmission, such as DRD2 (Gerra et al., 2018), DAT1 (Grzywacz et al., 2020) and COMT (Van der Knaap et al., 2014) and in the CBI and CB2 receptors genes part of the endocannabinoid system (Rotter et al., 2012; Tao et al., 2020). The latter playing an important role in brain development and synaptic transmission.

A recent study investigated the effect of heavy CU with and without tobacco on EWAS (Osborne et al., 2020). The analyses in the sample with both cannabis and tobacco use identified differentially methylated sites in 2 genes, AHRR and F2RL, previously reported to be affected by tobacco exposure. Within the sample of cannabis users without tobacco, while none of the differentially methylated loci reached EWAS significance, an exploratory analysis showed enrichment for genes involved in the signalling pathway, including glutamatergic transmission, brain function and mood disorders. Moreover, these exploratory analyses show two differentially methylated sites significantly associated with both only CU and cannabis with tobacco, which are within the MARC2 gene. The latter previously linked to adverse effects to antipsychotics in schizophrenia (Åberg et al., 2010) and within the CUX1 gene which is involved in neuronal development (Platzer et al., 2018).

Furthermore, recent whole blood and cell-specific Methylome-wide association studies (MWAS) from a sample of adolescents with CU disorder pointed at many methylation sites
relevant to brain function and to neurodevelopment (Clark et al., 2021). These included CpGs located in the CLMN gene and the SENP7 gene, expressed in the brain and playing a role in brain developmental and synaptic function and organisation (Juarez-Vicente, Luna-Pelaez, & Garcia-Dominguez, 2016; Marzinke & Clagett-Dame, 2012). Interestingly, the pathway analyses based on the cell type-specific significant DNAm changes associated with CU implicated pathways such as the Slit-Robo signalling (granulocytes) under the regulatory control of the endocannabinoid system during brain cortical development (Alpár et al., 2014), the ErbB signalling pathway (T-cell) and pathways involved in DNA repair (B-cell) (Clark et al., 2021).

Inflammation, oxidative stress, synaptic plasticity and neurogenesis

Childhood adversity
A number of EWAS studies conducted in clinical samples have reported an association between exposure to CA and DNAm changes across genes involved in inflammation. For instance, a study (Prados et al., 2015) found a positive correlation between the IL17RA DNAm and CA in a Borderline PD and MDD sample. Other evidence suggests a negative correlation between DNAm in genes enriched for immune pathways (such as TLR1 and TLR3) and CA in PTSD subjects (Uddin et al., 2010); while the TNFRSF13C gene was differently methylated between Borderline PD participants with and without CA (Arranz et al., 2021) (See Online Supplementary Table S1 (SM) – EWAS section).

Candidate genes studies have linked CA with DNAm changes in BDNF (Moser et al., 2015; Thaler et al., 2014; Weder et al., 2014), consistently with EWAS data reporting DNAm changes affecting genes involved in neurogenesis (Prados et al., 2015; Uddin et al., 2010). For instance, three EWAS studies in BD (Comes et al., 2019), Borderline PD (Arranz et al., 2021) and MDD (Lutz et al., 2017) have consistently shown changes in DNAm in genes from the POU family that are associated with CA (POU6f2, POU5f1 and POU3f1 respectively), which are genes involved in myelination and neurogenesis (Online Supplementary Table S1 (SM) – EWAS section).

A recent EWAS study found differences in DNAm of the GGT6 gene that were associated with exposure to CA in a sample of Borderline PD patients; GGT6 is key for glutathione homeostasis (Arranz et al., 2021), it is also the main antioxidant and redox regulator that has previously been associated with SCZ aetiopathogenesis (Steullet et al., 2016). Further evidence is summarised in Online Supplementary Table S2 (SM).

As a whole, candidate gene and EWAS studies suggest a link between CA and genes involved in the inflammatory and neurogenesis pathways, with some preliminary evidence suggesting a link between CA and DNAm and oxidative stress genes (Fig. 1).

Cannabis use
The largest to date case–control study to examine the effect of lifetime CU on DNAm reported an epigenome-wide-significantly differentially methylated CpG site within the CEMIP gene (Markunas et al., 2020). The CEMIP gene, involved in hyaluronic catabolism, which has been shown to have an important role in inflammation, immune processes as well as associated with BD and SCZ previously (Petrey & de la Motte, 2014).

Other environmental exposures that can act as confounders in psychiatric epigenetic

Tobacco smoking
A number of publications have identified robust associations between tobacco smoking and DNAm (Elliott et al., 2014; Shenker et al., 2013; Tsaprouni et al., 2014; Zeilinger et al., 2013), with a number of genes (e.g. AHRR, F2RL3, GFI1 and MYO1G) replicated across studies.

The confounding effect of smoking is clearly evidenced in an EWAS study on peripheral blood of SCZ patients (Hannon et al., 2016). A similar study examining the impact of CA on the epigenome in a general population found that tobacco consumption was an important confounding when examining the signature of CA (Marzi et al., 2018). Whether some of these epigenetic changes associated with tobacco exposure could also mediate the already reported link between tobacco use and increased risk of psychosis, it is an important question yet to be determined (Gurillo et al., 2015), and tobacco smoking should be accounted for in the future epigenetic studies in psychiatry.

Alcohol use and abuse
There is some initial evidence to suggest that alcohol use is associated with DNAm changes (Liu et al., 2016; Wang, Xu, Zhao, Gelernter, & Zhang, 2016; Weng, Wu, Lee, Hsu, & Cheng, 2015). Enrichment analyses examined DNAm in alcohol users have revealed enrichment in pathways related to neural degeneration (Weng et al., 2015), and in genes important for neurogenesis (NPDC1), inflammation (HERC5) and in GABA receptors (a receptor delta and B receptor subunit 1); all of which are pathways previously associated with different mental disorders, as shown in Fig. 1. However, studies rarely account for such covariates, which is currently a limitation of current literature.

Psychiatric medication
The extent of the data reporting the DNAm changes associated with psychiatric medication would require a separate review. Indeed, there is consistent evidence that pharmacological agents can trigger DNAm in similar or opposite directions than those attributed to the disease. For example, Lithium, Carbamazepine and Quetiapine, often prescribed for the treatment of BD, are associated with decrease methylation of SLC6A4 (Asai et al., 2013; Sugawara et al., 2015), in contrast with the hypermethylation reported in BD in that gene (Table 2). Similarly, studies who have investigated the effect of antipsychotic medication, have shown, on the one hand, that Haloperidol affects DNAm in leucocytes of SCZ patients (Melas et al., 2012), while on the other hand, a recent EWAS study showed that Clozapine exposure leads to DNAm differences in patients with treatment-resistant SCZ (Hannon et al., 2021) as compared to controls. Thus, it is key to consider the possibility that some of the changes in DNA pathways may be led by agents rather than the disease itself, highlighting the need to account for medication in future studies and to consider epigenetics as a potential mediating mechanism of action of the beneficial effects of medication in the brain.

Summary and outstanding questions
As illustrated in Fig. 1, many of the epigenetic dysregulations we report are transdiagnostic, such as those affecting the
serotonergic, inflammatory and neurogenesis pathways, while others such as the Glutamatergic/GABAergic pathway are shared between a couple of disorders (e.g. SCZ and ASD), or disorder specific such as the dopaminergic pathway in PDs. These are pathways that have been classically implicated in the aetio-pathogenesis of psychiatric phenotypes; additional emerging pathways such as oxidative stress remain to be further explored.

Moreover, CA, is transdiagnostically associated to psychiatry morbidty, and seems to play a role in the DNAm dysregulation of many of these pathways. Furthermore, the preliminary DNAm changes so far reported associated with CU affect pathways previously linked to psychosis, suggesting potential mediating venues to be tested in clinical populations (Fig. 1).

In addition, CA is associated with DNAm changes both in the general population (Kandaswamy et al., 2020) as well as in clinical samples with a psychiatric diagnosis (Online Supplementary Table S1 (SM)). This might suggest that the DNAm changes associated to CA exposure predate disease onset and could represent a marker of acquired psychiatric liability. However, evidence formally testing mediating pathways EWAS level between CA and the main clinical conditions is non-existent in humans. Candidate gene studies tend to find the inconsistent direction of the association between CA across disorders, or findings are inconsistent within disorders as shown in Fig. 2 and Table 2 and Online Supplementary Table S1 (SM). One explanation could be that there are other causative partners that are being missed in the equation, that may explain such inconsistency, such as the role of genotype, gene expression or a more thorough assessment of specific adversities in the context of protective factors and its link with more carefully selected clinical phenotypes.

The existing findings from epigenetics research need to be appraised in the context of well-known technical limitations epigenetics, such as the blood-brain inconsistencies, tissue-type specificity (Bakulski, Halladay, Hu, Mill, & Fallin, 2016; Nikolova & Hariri, 2015) and the candidate gene v. EWAS issue (see Palma-Gudiel, Córdova-Palomera, Leza, & Fañanás, 2015). Moreover, evidence suggests that variation in DNAm depends not only on the environment, but also on genetic factors (Bell & Spector, 2012). Although some studies presented in this review have found evidence that some genotypic variation in some risk alleles can influence DNAm (Klengel et al., 2013; Melas et al., 2013; Perroud et al., 2016), EWAS addressing the joint effect of genotype and environment are still in its infancy (Min et al., 2021). Addressing this issue will prove methodologically challenging, but methods quantifying the genetic influences on DNAm, such as the methylation quantitative trait loci (mQTL) should be used in relation to the presence of environmental insults. Moreover, studies included in this work are often small (Online Supplementary Table S1 (SM)) and thus underpowered, except some exceptions (Hannon et al., 2021), which presents the need to create collaborative efforts allowing meta-analysis of comparable epigenetic data. Furthermore, evidence of the environmental exposure impact through epigenetic modification in psychiatric diseases or phenotypes is still limited, with studies focusing mainly on exposure to CA and only preliminary results of the effect of cannabis. Given the replicated but differential impact of multiple environmental risk factors in major psychiatric disorders (Rodriguez et al., 2021), future studies exploring epigenetic variation as a mediator between genetic vulnerability and various environmental factors (not only CA) should be addressed, using novel methods specifically developed for mediation using EWAS data (Liu et al., 2021). Another important factor is the phenotypic characterisation for environmental exposure. For instance, most of the studies in this work have used broad measures of adversity, using a composite cumulative score, rather than differentiating between neglect of abuse. The same can be said for the measures of CU which little reflects the level of exposure none to affect psychiatric liability. Moreover, the outcomes are often considered as SCZ, or MDD or even major psychoses (combining SCZ & BD), which are extremely heterogeneous entities, involving micro-phenotypes (Maj et al., 2021), and which accordingly may have very different biological underpinnings. Evidence is showing that there are some levels of specificity between adversity subtypes and symptoms domains, for example, abuse is more related to positive symptoms while neglect is not (Alameda et al., 2021) and that CU is associated with paranoia (Freeman et al., 2005).

Thus, using a composite measure of CA and broadly defined conditions when trying to understand specific mediating epigenetic pathways may consider such specific links between environment and psychopathology first. Accordingly, this work suggests that some biological pathways are operating transdiagnostically, and therefore a phenotypic characterisation based on clinical dimensions may be more biologically informative than diagnostic categorisations. Furthermore, the timing of environmental exposure should be addressed, given evidence that a disruption in epigenetic programming occurs across different time windows throughout the life span (Massicotte, Whitelaw, & Angers, 2011). In this line, the lack of information on the timing of trauma and of CU initiation could explain some of the inconsistencies mentioned in our review (Fig. 2). For example, we reviewed studies showing increased methylation of the serotonin transporter in depressed individuals exposed to trauma (usually when adversity occurs before adulthood), which contrasts with the lower methylation in the same gene in PTSD, when exposure tends to be later in life.

Conclusions

Future Research should include the influence of gender and how it can modulate the links between DNAm and mental disorders, or how it can affect the influence of CA on DNAm. More effort should go towards designing studies that integrate genetic data with the often-neglected effect of environmental exposures (e.g. recreational drugs and psychotropic medication). Specifically, collaborative efforts between geneticists, epigeneticists and epidemiologists will lead to increased understanding of how the DNAm changes mapping to specific pathways, might mediate the biological link between environmental exposures and increased liability to specific or transdiagnostic psychiatric morbidity.

Supplementary material. The supplementary material for this article can be found at https://doi.org/10.1017/S0033291721005559.

Acknowledgements. We thank our funding bodies. Dr Luis Alameda was supported at the beginning of the preparation of the current work by the Swiss national Foundation (P2LAP3 171804). Dr Chloe Wong is supported by a joint grant from the Economic and Social Research Council (ESRC) and Biotechnology and Biological Sciences Research Council [ES/N000277/1]. Dr Marta Di Forti work is supported by the Medical Research Council SRF MR/T007818/1.

References

Abdolmaleky, H. M., Cheng, K.-H., Faraoe, S. V., Wilcox, M., Glatt, S. J., Gao, F., … Carnevale, J. (2006). Hypomethylation of MB-COMT promoter is a
influence of MAO-A DNA methylation on treatment response. *Journal of neural transmission*, 122(1), 99–108.

Duffy, A., Goodday, S. M., Keown-Stonean, C., Scotti, M., Maitra, M., Nagy, C., … Turecki, G. (2019). Epigenetic markers in inflammation-related genes associated with mood disorder: A cross-sectional and longitudinal study in high-risk offspring of bipolar parents. *International Journal of Bipolar Disorders*, 7 (1), 1–8.

Elliott, H. R., Tillin, T., McArdle, W. L., Ho, K., Duggirala, A., Frayling, T. M., … Belton, C. L. (2014). Differences in smoking-associated DNA methylation patterns in South Asians and Europeans. *Clinical Epigenetics*, 6(1), 4. https://doi.org/10.1186/1868-7083-6-4

Engdahl, E., Alavian-Ghanavini, A., Forsell, Y., Lavebratt, C., & Rüegg, J. (2021). Childhood adversity increases methylation in the GRIN2B gene. *Journal of Psychiatry Research*, 132, 38–43. https://doi.org/10.1016/j.jpsychires.2020.09.022

Fachim, H. A., Loureiro, C. M., Corsi-Zueilli, F., Shuhama, R., Louzada-Junior, P., Menezes, P. R., … Reynolds, G. P. (2019). GRIN2B promoter methylation deficits in early-onset schizophrenia and its association with cognitive function. *Epigenomics*, 11(4), 401–410.

Fachim, H. A., Srirawat, U., Dalton, C. F., & Reynolds, G. P. (2018). Parvalbumin promoter hypermethylation in postmortem brain in schizophrenia. *Epigenomics*, 10(5), 519–524.

Farrell, C., Doolin, K., O’Leary, N., Jairaj, C., Roddy, D., Tozzi, L., … Nemoda, Z. (2018). DNA Methylation differences at the glucocorticoid receptor gene in depression are related to functional alterations in hypothalamic–pituitary–adrenal axis activity and to early life emotional abuse. *Psychiatry Research*, 265, 341–348.

Fikri, R. M. N., Norlelawati, A. T., El-Huda, A. R. N., Hanisah, M. N., Kartini, A., Norsidah, K., & Zamzila, A. N. (2017). Reelin (RELN) DNA methylation in the peripheral blood of schizophrenia. *Journal of Psychiatric Research*, 88, 28–37.

Freeman, D., Garety, P. A., Bebbington, P. E., Smith, B., Rollinson, R., Fowler, D., … Dunn, G. (2005). Psychological investigation of the structure of paranoia in a non-clinical population. *The British Journal of Psychiatry*, 186(5), 427–435.

Friedling, H., Romer, K. D., Scholz, S., Mittelbach, F., Wilhelm, J., De Zwaan, M., … Bleich, S. (2010). Epigenetic dysregulation of dopaminergic genes in eating disorders. *International Journal of Eating Disorders*, 43(7), 577–583. https://doi.org/10.1002/eat.20745

García-Giménez, J. L., Roma-Mateo, C., Pérez-Machado, G., Peiro-Chova, L., Gurillo, P., Jauhar, S., Murray, R. M., & MacCabe, J. H. (2015). Does tobacco consumption influence of MAO-A DNA methylation on treatment response. *Journal of neural transmission*, 122(1), 99–108.
Liu, Z., Shen, J., Barfield, R., Schwartz, J., Baccarelli, A. A., & Lin, X. (2021). A DNA methylation biomarker of alcohol consumption and its expression profile with the risk of schizophrenia. *Psychiatric Genetics, 23*(5), 183–187.

Kuan, P., Waszczuk, M., Kotov, R., Marsit, C., Guffanti, G., Gonzalez, A., … Luft, B. (2017). An epigenome-wide DNA methylation study of PTSD and depression in world trade center responders. *Translational Psychiatry, 7*(6), e1158–e1158.

Labonte, B., Azoulay, N., Yerko, V., Turecki, G., & Brunet, A. (2014). Epigenetic modulation of glucocorticoid receptors in posttraumatic stress disorder. *Translational Psychiatry, 4*(3), e368.

Law, A. J., Wang, Y., Sei, Y., O’Donnell, P., Piantadosi, P., Papaleo, F., … Vakkalanl, B. (2012). Neuroegulin-1-erbB4-p13K signaling in schizophrenia and phosphoinositide 3-kinase-p110δ inhibition as a potential therapeutic strategy. *Proceedings of the National Academy of Sciences, 109*(30), 12165–12170.

Lin, C.-C., & Huang, T.-L. (2020). Brain-derived neurotrophic factor and mental disorders. *Biomedical Journal, 43*(2), 134–142.

Lindert, J., von Ehrenstein, O. S., Grashow, R., Gal, G., Braehler, E., & Weisskopf, M. G. (2014). Sexual and physical abuse in childhood is associated with depression and anxiety over the life course: Systematic review and meta-analysis. *International Journal of Public Health, 59*(2), 359–372. https://doi.org/10.1007/s00038-013-0519-5

Liu, C., Marioni, R., Hedman, Å. K., Pfeiffer, L., Tsai, P., Reynolds, L., … Tanaka, T. (2016). A DNA methylation biomarker of alcohol consumption. *Molecular Psychiatry, 23*, 422–433.

Liu, J., Chen, J., Ehrlich, S., Walton, E., White, T., Perrone-Bizzozero, N., … Law, A. J., Wang, Y., Sei, Y., O’Labonte, B., Azoulay, N., Yerko, V., Turecki, G., & Brunet, A. (2014). Epigenetic aberrations in leukocytes of patients with schizophrenia: Association of global DNA methylation with antipsychotic drug treatment and disease onset. *The FASEB Journal, 26*(6), 2712–2718.

Meh, A. F., Wei, Y., Wong, C. C., Stjoholm, L. K., Åberg, E., Mühl, J., … Lavrebratt, C. (2013). Genetic and epigenetic associations of MAOA and NR3C1 with depression and childhood adversities. *International Journal of Neuropsychopharmacology, 16*(7), 1513–1528.

Meyer, J. H., Ginovart, N., Boorvaria, E., Sagratì, S., Hussey, D., Garcia, A., … Soule, H. (2006). Elevated monoamine oxidase a levels in the brain: An explanation for the monoamine imbalance of major depression. *Archives of General Psychiatry, 63*(11), 1209–1216.

Mill, J., Tang, T., Kaminisky, Z., Khare, T., Yazdanpanah, S., Bouchard, L., … Petronis, A. (2008). Epigenomic profiling reveals DNA-methylation changes associated with major psychosis. *American Journal of Human Genetics, 82*(3), 696–711. https://doi.org/10.1016/j.ajhg.2008.01.008

Min, J. L., Hemani, G., Hannon, E., Dekkers, K. F., Castillo-Fernandez, J., Luikj, R., … Suderman, M. (2021). Genomic and phenotypic insights from an atlas of genetic effects on DNA methylation. *Nature Genetics, 53*(9), 1311–1321.

Misjak, R., Karpinski, P., Smida, E., Grzegorzek, T., Jabłoński, M., Cyranka, K., … Frydecka, D. (2020). Adverse childhood experiences and methylation of the FKBP5 gene in patients with psychiatric disorders. *Journal of Clinical Medicine, 9*(12), 1097. https://doi.org/10.3390/jcm9121097

Montano, C., Taub, M. A., Jaffe, A., Briem, E., Feinberg, J. L., Tryggvadottir, R., … Feinberg, A. P. (2016). Association of DNA methylation differences with schizophrenia in an epigenome-wide association study. *JAMA Psychiatry, 73*(5), 506–514. https://doi.org/10.1001/jamapsychiatry.2016.0144

Moser, D. A., Paoloni-Giacobino, A., Stenz, L., Adouan, W., Manini, A., Suardi, F.. . Rusconi-Serpa, S. (2015). BDNF methylation and maternal brain activity in a violence-related sample. *PloS One, 10*(12), e0143427.

Murphy, B. C., O’Reilly, R. L., & Singh, S. M. (2005). Site-specific cytosine methylation in S-COMT promoter in 31 brain regions with implications for studies involving schizophrenia. *American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 133*(1), 37–42.

Nagy, C., Suderman, M., Yang, J., Szif, M., McPharav, N., Ernst, C., & Turecki, G. (2015). Astrocytic abnormalities and global DNA methylation patterns in depression and suicide. *Molecular psychiatry, 20*(3), 320–328.

Nikolova, Y. S., & Hariri, A. R. (2015). Can we observe epigenetic effects on human brain function? *Trends in Cognitive Sciences, 19*(7), 366–373.

Nishioka, M., Bundo, M., Koike, S., Takizawa, R., Kakiuchi, C., Araki, T., … Iwamoto, K. (2013). Comprehensive DNA methylation analysis of periph-eral blood outgrowth in murine neuroblastoma (Neuro2a) cells. *Experimental Cell Research, 318*(1), 85–93.

Nohesara, S., Ghadirivasfi, M., Mostafavi, S., Eskandari, M.-R., Ahmadkanhiha, H., Thaigalingam, S., & Abdolmalehy, H. M. (2011). DNA Hypomethylation of MB-COMT promoter in the DNA derived from saliva in schizophrenia and bipolar disorder. *Journal of Psychiatric Research, 45*(11), 1432–1438.
Nöthling, J., Malan-Müller, S., Abrahams, N., Hemmings, S. M. J., & Seedat, S. (2020). Epigenetic alterations associated with childhood trauma and adult mental health outcomes: A systematic review. The World Journal of Biological Psychiatry, 21(7), 493–512.

Nour El Huda, A. R., Norsidah, K. Z., Nabil Fikri, M. R., Hanish, M. N., Kartini, A., & Norrelawati, A. (2018). DNA Methylation of membrane-bound catechol-O-methyltransferase in Malaysian schizophrenia patients. Psychiatry Clinical Neuroscience, 72(4), 266–279.

Numata, S., Ye, T., Herman, M., & Lipska, B. K. (2014). DNA Methylation changes in the postmortem dorsolateral prefrontal cortex of patients with schizophrenia. Frontiers in Genetics, 5, 280.

Olsson, C., Foley, D., Parkinson-Bates, M., Byrnes, G., McKenzie, M., Patton, G., … Saffery, R. (2010). Prospects for epigenetic research within cohort studies of psychological disorder: A pilot investigation of a peripheral cell marker of epigenetic risk for depression. Biological Psychology, 83(2), 159–165.

Osborne, A. J., Pearson, J. F., Noble, A. J., Gemmell, N. J., Horwood, L. J., Boden, J. M., … Kennedy, M. A. (2020). Genome-wide DNA methylation analysis of heavy cannabis exposure in New Zealand longitudinal cohort. Translational Psychiatry, 10, 114. http://dx.doi.org/10.1038/s41398-020-0800-3

Palma-Gudiel, H., Córdova-Palomera, A., Leza, J. C., & Ñañas, L. (2015). Glucocorticoid receptor gene (NR3C1) methylation processes as mediators of early adversity in stress-related disorders causality: A critical review. Neuroscience & Biobehavioral Reviews, 55, 520–535.

Pantaleone, P. M., & Pertsemlidis, A. (2013). Obesity and epigenetics: An overview. Annals of Translational Medicine, 1, 100. http://dx.doi.org/10.3978/j.issn.2291-9615.2013.03.001

Peng, H., Zhu, Y., Strachan, E., Fowler, E., Bacus, T., Roy-Byrne, P., … Zhao, J. (2018). Childhood trauma, DNA methylation of stress-related genes, and depression: Findings from two monozygotic twin studies. Psychosomatic Medicine, 80(7), 599–608.

Perez-Cornago, A., Mansego, M. L., Zule, M. A., & Martinez, J. A. (2014). DNA Hypermethylation of the serotonin receptor type-2a gene is associated with a worse response to a weight loss intervention in subjects with metabolic syndrome. Nutrients, 6(6), 2387–2403.

Perkins, D. O., Jeffries, C. D., & Do, K. Q. (2020). Potential roles of redox dysregulation in the development of schizophrenia. Biological Psychiatry, 88(4), 326–336.

Perroud, N., Paoloni-Giacobino, A., Prada, P., Olie, E., Salzmann, A., & Nicastro, R. (2011). Increased methylation of glucocorticoid receptor gene (NR3C1) in adults with a history of childhood maltreatment: A link with the severity and type of trauma. Translational Psychiatry, 1, 59. https://doi.org/10.1038/tp.2011.60

Perroud, N., Zewdie, S., Stenz, L., Adouan, W., Bavamian, S., & Prada, P. (2016). Methylation of serotonin receptor 3a in Adhd, borderline personality, and bipolar disorders: Link with severity of the disorders and childhood maltreatment. Depression and Anxiety, 33(1), 45–55. https://doi.org/10.1002/da.22406

Petry, A. C., & de la Motte, C. A. (2014). Hyaluronan, a crucial regulator of neurodevelopmental origin for schizophrenia. Genome Biology, 15(10), 483.

Pjetri, E., Dempster, E., Collier, D. A., Treasure, J., Kas, M. J., Mill, J., … Schmidt, U. (2013). Quantitative promoter DNA methylation analysis of four candidate genes in anorexia nervosa: A pilot study. Journal of Psychiatry Research, 47(2), 280–282. https://doi.org/10.1016/j.jpsychires.2012.10.007

Platzer, K., Cogné, B., Hague, J., Marcelis, C. L., Mitter, D., Oberndorff, K., … van der Smagt, J. J. (2018). Haploinsufficiency of CUX1 causes nonsyndromic global developmental delay with possible catch-up development. Annals of Neurology, 84(2), 280–207.

Prados, J., Stenz, L., Courtet, P., Prada, P., Nicastro, R., & Adouan, W. (2015). Borderline personality disorder and childhood maltreatment: A genome-wide methylation analysis. Genes Brain Behaviour, 14(2), 177–188. https://doi.org/10.1111/gbb.12197

Provenzi, L., Giodra, R., Beri, S., & Montiroso, R. (2016). SLCAa4 Methylation as an epigenetic marker of life adversity exposures in humans: A systematic review of literature. Neuroscience & Biobehavioral Reviews, 71(Suppl C), 7–20. https://doi.org/10.1016/j.neubiorev.2016.08.021

Pun, F. W., Zhao, C., Lo, W. S., Ng, S. K., Tsang, S. Y., Nimigean, V., … Xue, H. (2011). Imprinting in the schizophrenia candidate gene GABRB2 encoding GABA A receptor β 2 subunit. Molecular Psychiatry, 16(5), 557–568.

Radtke, K. M., Schauer, M., Gunter, H. M., Ruf-Leuschner, M., Sill, J., Meyer, A., & Elbert, T. (2015). Epigenetic modifications of the glucocorticoid receptor gene are associated with the vulnerability to psychopathology in childhood maltreatment. Translational Psychiatry, 5, e571.

Rahman, I., Marwick, J., & Kirkham, P. (2004). Redox modulation of chromatin remodeling: Impact on histone acetylation and deacetylation, NF-κB and pro-inflammatory gene expression. Biochemical Pharmacology, 68(6), 1255–1267.

Ramaswami, G., Won, H., Gandal, M. J., Haney, J., Wang, J. C., Wong, C. C. Y., … Geschwind, D. H. (2020). Integrative genomics identifies a convergent molecular subtype that links epigenomic with transcriptomic differences in autism. Nature Communications, 11(1), 4873. https://doi.org/10.1038/s41467-020-18526-1

Relton, C. L., & Smith, G. D. (2010). Epigenetic epidemiology of common complex disease: Prospects for prediction, prevention, and treatment. PLoS Medicine, 7(10), e1000356.

Ripke, S., Neale, B. M., Corvin, A., Walters, J. T., Farih, K.-H., Holmans, P. A., … Huang, H. (2014). Biological insights from 108 schizophrenia-associated genetic loci. Nature, 517(7510), 421–427.

Ripke, S., Wray, N. R., Lewis, C. M., Hamilton, S. P., Weissman, M. M., Breen, G., … Cichon, S. (2013). A mega-analysis of genome-wide association studies for major depressive disorder. Molecular Psychiatry, 18(4), 497.

Rodriguez, V., Alameda, L., Trotta, G., Spinazzola, E., Marino, P., Matheson, S. L., … Vassos, E. (2021). Environmental risk factors in bipolar disorder and psychotic depression: A systematic review and meta-analysis of prospective studies. Schizophrenia Bulletin, 47(4), 959–974.

Rotter, A., Bayerlein, K., Hansbauer, M., Weiland, J., Sperling, W., Kornhuber, J., & Biermann, T. (2012). CB1 And CB2 receptor expression and promoter methylation in patients with Cannabis dependence. European Addiction Research, 19(1), 13–20. http://dx.doi.org/10.1159/000338642

Ruzicka, W. B., Subburajiu, S., & Benes, F. M. (2015). Circuit-and diagnosis-specific DNA methylation changes at γ-aminobutyric acid–related genes in postmortem human hippocampus in schizophrenia and bipolar disorder. JAMA Psychiatry, 72(6), 541–551.

Sadah, N., Spielberg, J. M., Logue, M. W., Wolf, E. J., Smith, A. K., Lusk, J., … McGlinchey, R. E. (2016a). SKA2 Methylation is associated with decreased prefrontal cortical thickness and greater PTSD severity among trauma-exposed veterans. Molecular Psychiatry, 21(3), 357–363.

Sadah, N., Wolf, E. J., Logue, M. W., Hayes, J. P., Stone, A., Griffin, L. M., … Miller, M. W. (2016b). Epigenetic variation at SKA2 predicts suicide phenotypes and internalizing psychopathology. Depression and Anxiety, 33(4), 308–315.

Schechter, D. S., Moser, D. A., Paoloni-Giacobino, A., Stenz, L., Gex-Fabry, M., Aue, T., … Manini, A. (2015). Methylation of NR3C1 is related to maternal PTSD, parenting stress and maternal medial prefrontal cortical activity in response to child separation among mothers with histories of violence exposure. Frontiers in Psychology, 6, 690.

Schiele, M. A., Kollert, L., Lesch, K.-P., Arolt, V., Zwanzger, P., Deckert, J., … Domschke, K. (2019). Hypermethylation of the serotonin transporter gene promoter in panic disorder—epigenetic imprint of comorbid depression? European Neuropsychopharmacology, 29(10), 1161–1167.

Schlie, M. A., Thiel, C., Deckert, J., Zaudig, M., Berberich, G., & Domschke, K. (2020). Monoamine oxidase A hypomethylation in obsessive-compulsive disorder: Reversibility By successful psychotherapy? International Journal of Neuropsychopharmacology, 23(S1), 319–323.
Schlie, M. A., Ziegler, C., Kollett, L., Katzorke, A., Schartner, C., Busch, Y., … Deckert, J. (2018). Plasticity of functional MAOA gene methylation in accro- phobia. International Journal of Neuropsychopharmacology, 21(9), 822–827.

Schmack, G., Schorpp, K., Kutzner, K., Gehring, T., Brenke, J. K., Hadian, K., & Krapmann, D. (2017). YODI/TRAFA6 Association balances p62-dependent IL-1 signaling to NF-κB. Elife, 6, e22416.

Selvaraj, S., Arnone, D., Cappai, A., & Howes, O. (2014). Alterations in the serotonin system in schizophrenia: A systematic review and meta-analysis of postmortem and molecular imaging studies. Neuroscience & Biobehavioral Reviews, 45, 233–245.

Shenker, N. S., Polidoro, S., van Veldhoven, K., Sacerdote, C., Riccieri, F., Birrell, M. A., … Flanagan, J. M. (2013). Epigenome-wide association study in the European prospective investigation into cancer and nutrition (EPIC-Turin) identifies novel genetic loci associated with smoking. Hum Molecular Genetics, 22(5), 843–851. https://doi.org/10.1093/hmg/ddq488

Shih, J., & Thompson, R. (1999). Monoamine oxidase in neuropsychiatry and behavior. American Journal of Human Genetics, 65(3), 593.

Shimada-Sugimoto, M., Otowa, T., Miyagawa, T., Umekage, T., Kawamura, Y., Bundo, M., … Kiyai, H. (2017). Epigenome-wide association study of DNA methylation in panic disorder. Clinical epigenetics, 9(1), 1–11.

Sideli, L., Quigley, H., La Cascia, C., & Murray, R. M. (2020a). Cannabis use and the risk for psychosis and affective disorders. Journal of Dual Diagnosis, 16(1), 22–42.

Sideli, L., Troタイトルを截断

Sugawara, H., Bundo, M., Asai, T., Sunaga, F., Ueda, J., Iwamoto, K., … Iwamoto, K. (2015). Effects of quetiapine on DNA methylation in neuroblastoma cells. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 56, 117–121.

Sugawara, H., Iwamoto, K., Bundo, M., Ueda, J., Miyauuchi, T., Komori, A., … Okazaki, Y. (2011). Hypermethylation of serotonin transporter gene in bipolar disorder detected by epigenome analysis of discordant monozygotic twins. Translational Psychiatry, 17(7), e24–e24.

Tamura, Y., Kunugi, H., Ohashi, J., & Hohjoh, H. (2007). Epigenetic aberration of the human REelin gene in psychiatric disorders. Molecular Psychiatry, 12(6), 593–600.

Tao, R., Li, C., Jaffe, A. E., Shin, J. H., Deep-Soboslay, A., Yamin, R., … Kleinman, J. E. (2020). Cannabinoid receptor CNR1 expression and DNA methylation in human prefrontal cortex, hippocampus and caudate in brain development and schizophrenia. Translational Psychiatry, 10(1), 158. http://dx.doi.org/10.1038/s41398-020-0832-8

Thaler, L., Gauvin, L., Joobber, R., Gropleu, P., Guzman, R., & Ambalavanan, A. (2014). Methylation of BDNF in women with bulimic eating syndromes: associations with childhood abuse and borderline personality disorder. Prog Neuro-Psychopharmacol Biol Psychiatry, 54, 43–49. https://doi.org/10.1016/j.pnpb.2014.04.010

Thaler, L., & Steiger, H. (2017). Eating disorders and epigenetics. Advances in Experimental Medicine and Biology, 978, 93–103. https://doi.org/10.1007/978-3-319-53889-1_5

Thomas, M., Knoblich, N., Wallisch, A., Glowacz, K., Becker-Sadzio, J., Gundel, F., … Nieratschker, V. (2018). Increased BDNF methylation in saliva, but not blood, of patients with borderline personality disorder. Clinical Epigenetics, 10(1), 1–12.

Thuné, H., Recasens, M., & Uhlaas, P. J. (2016). The 40-Hz auditory steady-state response in patients with schizophrenia: A meta-analysis. JAMA Psychiatry, 73(11), 1145–1153.

Tozzi, L., Farrell, C., Bojoi, L., Doolin, K., Nemoda, Z., Syf, M., … Frodl, T. (2018). Epigenetic changes of FKBP5 as a link connecting genetic and environmental risk factors with structural and functional brain changes in Major depression. Neuropsychopharmacology, 43(5), 1138–1145. https://doi.org/10.1038/npp.2017.290

Tsaprouni, L. G., Yang, T. P., Bell, J., Dick, K. J., Kanoni, S., Nisbet, J., … Deloukas, P. (2014). Cigarette smoking reduces DNA methylation levels at multiple genomic loci but the effect is partially reversible upon cessation. Epigenetics, 9(10), 1382–1396. https://doi.org/10.4161/15592294.2014.969637

Uddin, M., Aiello, A. E., Wildman, D. E., Koenen, K. C., Pavelec, G., de Los Santos, R., … Gaia, S. (2010). Epigenetic and immune function profiles associated with posttraumatic stress disorder. Proceedings of the National Academy of Sciences, 107(20), 9470–9475.

Ursini, G., Cavallari, T., Fazio, L., Angrisano, T., Iacovelli, L., Porcelli, A., … Gelao, B. (2016). BDNF Rs6265 methylation and genotype interact on risk for schizophrenia. Epigenetics, 11(1), 11–23.

Van der Knap, L., Schaefer, J., Franken, I., Verhulst, F., van Oort, F., & Riese, H. (2014). Catechol-O-methyltransferase gene methylation and substance use in adolescents: The TRAILS study. Genes, Brain and Behavior, 13(7), 618–625.

van Os, J., Kenis, G., & Rutten, B. P. (2010). The environment and schizophrenia. Nature, 468(7321), 203–212. https://doi.org/10.1038/nature09563

Van Os, J., Rutten, B. P., & Poulton, R. (2008). Gene-environment interactions in schizophrenia: Review of epidemiological findings and future directions. Schizophrenia Bulletin, 34(6), 1066–1082. https://doi.org/10.1093/schbul/sbn050

Walton, E., Liu, J., Hass, J., White, T., Scholz, M., Roessner, V., … Ehrlich, S. (2014). MB-COMT promoter DNA methylation is associated with working-memory processing in schizophrenia patients and healthy controls. Epigenetics, 9(8), 1101–1107.

Wang, F., Xu, H., Zhao, H., Gelernter, J., & Zhang, H. (2016). DNA co-methylation modules in postmortem prefrontal cortex tissues of European Australians with alcohol use disorders. Scientific Reports, 6, 19430. https://doi.org/10.1038/srep19430

Wang, W., Feng, J., Ji, C., Mu, X., Ma, Q., Fan, Y., … Zhu, F. (2017). Increased methylation of glucocorticoid receptor gene promoter 1F in peripheral blood of patients with generalized anxiety disorder. Journal of Psychiatric Research, 91(Supp C), 18–25. https://doi.org/10.1016/j.jpsychires.2017.01.019

Weder, N., Zhang, H., Jensen, K., Yang, B. Z., Simen, A., Jackowski, A., … Erepelchukova, F. (2014). Child abuse, depression, and methylation in genes involved with stress, neural plasticity, and brain circuitry. Journal of the American Academy of Child & Adolescent Psychiatry, 53(4), 417–424. e415.

Weng, J. T., Wu, L. S., Lee, C. S., Hsu, P. W., & Cheng, A. T. (2015). Integrative epigenetic profiling analysis identifies DNA methylation changes associated with chronic alcohol consumption. Computational Biology & Medicine, 64, 299–306. https://doi.org/10.1016/j.compbiomed.2014.12.003

Wesarg, C., Van Den Akker, A. L., Oei, N. Y., Hoeve, M., & Wiers, R. W. (2020). Identifying pathways from early adversity to psychopathology: A review on dysregulated HPA axis functioning and impaired self-regulation in early childhood. European Journal of Developmental Psychology, 17(6), 808–827. https://doi.org/10.1080/17405629.2020.1775749

Wong, C. Y., Smith, R., Hannon, E., Ramaswami, G., Parikhshak, N., Assary, E., … Sun, W. (2018). Genome-wide DNA methylation profiling identifies convergent molecular signatures associated with idiopathic and syndromic forms of autism in postmortem human brain tissue. 28(13), 394387.

Wong, C. C. Y., Smith, R. G., Hannon, E., Ramaswami, G., Parikhshak, N. N., Assary, E., … Mill, J. (2019). Genome-wide DNA methylation profiling identifies convergent molecular signatures associated with idiopathic and syndromic autism in post-mortem human brain tissue. Human Molecular Genetics, 28(13), 2201–2211. https://doi.org/10.1093/hmg/ddz052

Wu, Y. E., Parikhshak, N. N., Belgard, T. G., & Geschwind, D. H. (2016). Genome-wide, integrative analysis implicates microRNA dysregulation in autism spectrum disorder. Nature Neuroscience, 19(11), 1463–1476.

Yu, Q., Jiang, M., Gu, S., Wang, F., & Yuan, B. (2020). Early life stress induced DNA methylation of monoamine oxidases leads to depressive-like behavior.
Yehuda, R., Flory, J. D., Bierer, L. M., Henn-Haase, C., Lehrner, A., Desarnaud, F., … Meaney, M. J. (2015). Lower methylation of glucocorticoid receptor gene promoter 1 F in peripheral blood of veterans with posttraumatic stress disorder. *Biological Psychiatry, 77*(4), 356–364.

Yong, W. S., Hsu, F. M., & Chen, P. Y. (2016). Profiling genome-wide DNA methylation. *Epigenetics Chromatin, 9*, 26. [https://doi.org/10.1186/s13072-016-0075-3](https://doi.org/10.1186/s13072-016-0075-3)

Yoshino, Y., Kawabe, K., Mori, T., Mori, Y., Yamazaki, K., Numata, S., … Ohmori, T. (2016). Low methylation rates of dopamine receptor D2 gene promoter sites in Japanese schizophrenia subjects. *The World Journal of Biological Psychiatry, 17*(6), 449–456.

Zellinger, S., Kuhnel, B., Klopp, N., Baurecht, H., Kleinschmidt, A., Gieger, C., … Illig, T. (2013). Tobacco smoking leads to extensive genome-wide changes in DNA methylation. *PLoS ONE, 8*(5), e63812. [https://doi.org/10.1371/journal.pone.0063812](https://doi.org/10.1371/journal.pone.0063812)

Zhai, J., Goldberg, J., Brenner, J. D., & Vaccarino, V. (2013). Association between promoter methylation of serotonin transporter gene and depressive symptoms: A monozygotic twin study. *Psychosomatic Medicine, 75*(6), 523–529.

Zhu, Y., Strachan, E., Fowler, E., Bacus, T., Roy-Byrne, P., & Zhao, J. (2020). Genome-wide profiling of DNA methyolme and transcriptome in peripheral blood monocytes for major depression: A Monozygotic Discordant Twin Study. *Transl Psychiatry, 9*(1), 215. [https://doi.org/10.1038/s41398-019-0550-2](https://doi.org/10.1038/s41398-019-0550-2)

Ziegler, C., Richter, J., Mahr, M., Gajewska, A., Schiele, M. A., Gehrmann, A., … Helbig-Lang, S. (2016). MAOA Gene hypomethylation in panic disorder—reversibility of an epigenetic risk pattern by psychotherapy. *Translational Psychiatry, 6*(4), e773–e773.

Zong, L., Zhou, L., Hou, Y., Zhang, L., Jiang, W., Zhang, W., … Deng, C. (2017). Genetic and epigenetic regulation on the transcription of GABRB2: Genotype-dependent hydroxymethylation and methylation alterations in schizophrenia. *Journal of Psychiatric Research, 88*, 9–17.